Phase III Randomized Controlled Trial to Compare LYL314, a Dual Targeting CD19/CD20 CAR T-Cell Product Candidate, Versus Investigator's Choice of CD19 CAR T-Cell Therapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Second-Line Setting
Categories (click each to see list of all clinical trials associated with that category): Cellular Therapy Support Service - CAR-T (ONC), Lymphoma/CLL (ONC)
Current Status: Not open
Phase: III
Principal Investigator: Lunning, Matthew
Contact Information:
Kellie Rinehart
kellie.rinehart@unmc.edu
Summary